A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog® in Subjects With Type 1 Diabetes
Abroad (travel likely)CompletedPHASE1
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Conditions
Diabetes · Diabetes Mellitus, Type 1
Locations
- Novo Nordisk Investigational Site, Atlanta, Georgia, United States